Original Article

You have full text access to this OnlineOpen article

The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel

  1. Thomas A. Hensing M.D.1,†,*,
  2. Amy H. Peterman Ph.D.2,
  3. Michael J. Schell Ph.D.1,
  4. Ji-Hyun Lee M.S.1,
  5. Mark A. Socinski M.D.1

Article first published online: 20 JUN 2003

DOI: 10.1002/cncr.11548

Issue

Cancer

Cancer

Volume 98, Issue 4, pages 779–788, 15 August 2003

Additional Information

How to Cite

Hensing, T. A., Peterman, A. H., Schell, M. J., Lee, J.-H. and Socinski, M. A. (2003), The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel. Cancer, 98: 779–788. doi: 10.1002/cncr.11548

Author Information

  1. 1

    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina

  2. 2

    Center on Outcomes Research and Education, Northwestern University, Chicago, Illinois

  1. †

    Fax: (847) 570-2336

*Thoracic Oncology Program, Evanston Northwestern Healthcare, 2650 Ridge Avenue, Evanston, IL 60201

Publication History

  1. Issue published online: 1 AUG 2003
  2. Article first published online: 20 JUN 2003
  3. Manuscript Accepted: 25 APR 2003
  4. Manuscript Revised: 17 APR 2003
  5. Manuscript Received: 28 JAN 2003

Funded by

  • Bristol-Myers Squibb Oncology

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (109K)

REFERENCES

  • 1
    Fry W, Phillips J, Menck H. Ten-year survey of lung cancer treatment and survival in hospitals in the United States. Cancer. 1999; 86: 1867–1876.
    Direct Link:
  • 2
    Hillner B, McDonald M, Desch C, Smith T, Penberthy L, Retchin S. A comparison of patterns of care of nonsmall cell lung carcinoma patients in a younger and Medigap commercially insured cohort. Cancer. 1998; 83: 1930–1937.
    Direct Link:
  • 3
    Earle C, Venditti L, Neumann P, et al. Who gets chemotherapy for metastatic lung cancer? Chest. 2000; 117: 1239–1246.
  • 4
    Smith T, Penberthy L, Desch C, et al. Differences in initial treatment patterns and outcomes of lung cancer in the elderly. Lung Cancer. 1995; 13: 235–252.
  • 5
    McKenna R. Clinical aspects of cancer in the elderly: treatment decisions, treatment choices, and follow-up. Cancer. 1994; 74: 2107–2117.
    Direct Link:
  • 6
    Hutchins L, Unger J, Crowley J, Coltman C, Albain K. Under representation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999; 341: 2061–2067.
  • 7
    Balducci L, Exterman M. Cancer chemotherapy in the older patient: what the medical oncologist needs to know. Cancer. 1997; 80: 1317–1322.
    Direct Link:
  • 8
    Balducci L, Extermann M. Management of cancer in the older person: a practical approach. Oncologist. 2000; 5: 224–237.
  • 9
    Socinski M. Chemotherapy for Stage IV non-small cell lung cancer. In: DetterbeckF, editor. Diagnosis and treatment of lung cancer: an evidence-based guide for the practicing clinician. Volume 1. Philadelphia: WB Saunders Company, 2001: 307–325.
  • 10
    The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst. 1999; 91: 66–72.
  • 11
    Frasci G, Lorusso V, Panza N, et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol. 2000; 18: 2529–2536.
  • 12
    Gridelli C, Perrone F, Cigolari S, Manzione L, Piantedose F, Barbera S. The MILES (Multicenter Italian Lung Cancer in the Elderly Study) Phase III trial: gemcitabine and vinorelbine versus vinorelbine and versus gemcitabine in elderly advanced non-small cell lung cancer [abstract]. Proc Am Soc Clin Oncol. 2001; 20: 1230a.
  • 13
    Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ. 1995; 311: 899–909.
  • 14
    Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002; 346: 92–98.
  • 15
    Kelly K, Crowley J, Bunn P, et al. Randomized Phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol. 2001; 19: 3210–3218.
  • 16
    Belani C, Natale R, Lee J, et al. Randomized Phase III trial comparing cisplatin/etoposide versus carboplatin/paclitaxel in advanced and metastatic non-small cell lung cancer [abstract]. Proc Am Soc Clin Oncol. 1998; 17: 455a.
  • 17
    Choy H, Shyr Y, Cmelak A. Patterns of practice survey for nonsmall cell lung carcinoma in the U.S. Cancer. 2000; 88: 1336–1346.
    Direct Link:
  • 18
    Kelly K, Crowley J, Bunn P, Livingston R, Gandara D. A randomized Phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in untreated advanced non-small cell lung cancer: a Southwest Oncology Group (SWOG) trial [abstract]. Proc Am Soc Clin Oncol. 1999; 18: 461a.
  • 19
    Socinski M, Schell M, Peterman A, et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second line therapy in advanced Stage IIIB/IV non-small cell lung cancer. J Clin Oncol. 2002; 20: 1335–1343.
  • 20
    Socinski M, Schell M, Bakri K, Kies M, Gillenwater H. Second-line low-dose weekly paclitaxel in patients with Stage IIIB/IV non-small cell lung cancer failing first line carboplatin/paclitaxel. Cancer. 2002; 95: 1265–1273.
    Direct Link:
  • 21
    Altman D, Lausen B, Sauerbrei W, Schumacher M. Dangers of using “optimal” cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst. 1994; 86: 289–294.
  • 22
    Gridelli C. The ELVIS trial: a Phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer. Elderly Lung Cancer Vinorelbine Italian Study. Oncologist. 2001; 1: 4–7.
  • 23
    Gridelli C, Cigolari S, Gallo C, et al. Activity and toxicity of gemcitabine and gemcitabine + vinorelbine in advanced non-small-cell lung cancer elderly patients: Phase II data from the Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trial. Lung Cancer. 2001; 31: 277–284.
  • 24
    Kubota K, Furuse K, Kawahara M, et al. Cisplatin-based combination chemotherapy for elderly patients with non-small-cell lung cancer. Cancer Chemother Pharmacol. 1997; 40: 469–474.
  • 25
    Oshita F, Kurata T, Kasai T, et al. Prospective evaluation of the feasibility of cisplatin-based chemotherapy for elderly lung cancer patients with normal organ functions. Jpn J Cancer Res. 1995; 86: 1198–1202.
  • 26
    Hickish T, Smith I, O'Brien M, Ashley S, Middleton G. Clinical benefit from palliative chemotherapy in non-small-cell lung cancer extends to the elderly and those with poor prognostic factors. Br J Cancer. 1998; 78: 28–33.
  • 27
    Langer C, Manola J, Bernado P, et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst. 2002; 94: 173–181.
  • 28
    Rinaldi M, De Marinis F, Ardizzona A. Correlation between age and prognosis in patients with advanced non small cell lung cancer treated with cisplatin containing chemotherapy: a retrospective multicenter study. Ann Oncol. 1994; 5(Suppl 8): 58.
  • 29
    Nakamura Y, Sekine I, Furuse K, Saijo N. Retrospective comparison of toxicity and efficacy in Phase II trials of 3-h infusions of paclitaxel for patients 70 years of age or older and patients under 70 years of age. Cancer Chemother Pharmacol. 2000; 46: 114–118.
  • 30
    Rosvold E, Langer C, McAleer C, Zipin H, Bonjo C, Ozols R. Advancing age does not exacerbate toxicity or compromise outcome in non-small cell lung cancer patients receiving paclitaxel-carboplatin [abstract]. Proc Am Soc Clin Oncol. 1999; 18: 478a.
  • 31
    Kelly K, Giarrita S, Hayes S, et al. Should older patients (pts) receive combination chemotherapy for advanced stage non-small cell lung cancer (NSCLC)? An analysis of Southwest Oncology Trials 9509 and 9308 [abstract]. Proc Am Soc Clin Oncol. 2001; 20: 329a.
View Full Article (HTML) Get PDF (109K)